A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication

Astellas Pharma Inc

Overview

The purpose of this study is to track changes in overactive bladder (OAB) medical regimen and/or OAB medication dosage requirements.

Subjects will complete a study specific survey questionnaire at Screening and the Month 1 through Month 6 visits. Subjects will be followed for 6 months.

Study Type

OBSERVATIONAL

Conditions

Overactive Bladder (OAB)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject has overactive bladder as determined by their prescribing physician * Subject is currently receiving pharmacotherapy for overactive bladder * Subject is willing to comply with required protocol/study requirements Exclusion Criteria: * Subject has a history of a clinically significant illness or medical condition prior to screening that would preclude participation in the study * Male subjects with Lower Urinary Tract Symptoms (LUTS) or Bladder Outlet Obstruction (BOO)

Outcomes

Primary Outcomes

Change in overactive bladder (OAB) medication/ treatment regimen

Time frame: 6 months

Reason for change in OAB medication/treatment regimen

Time frame: 6 months

Secondary Outcomes

Persistence of use of any OAB medication as reported by the Physician

Time frame: 6 months

Change in OAB medication including discontinuation of OAB medication as reported by the Physician

Time frame: 6 months

Subject reported efficacy

Measured by the Subject Survey Questionnaire

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.